IN2012DN00938A - - Google Patents

Info

Publication number
IN2012DN00938A
IN2012DN00938A IN938DEN2012A IN2012DN00938A IN 2012DN00938 A IN2012DN00938 A IN 2012DN00938A IN 938DEN2012 A IN938DEN2012 A IN 938DEN2012A IN 2012DN00938 A IN2012DN00938 A IN 2012DN00938A
Authority
IN
India
Prior art keywords
amino acid
acid sequence
sequence
toll
antibodies
Prior art date
Application number
Inventor
Jerome Dellacasagrande
Original Assignee
Opsona Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opsona Therapeutics Ltd filed Critical Opsona Therapeutics Ltd
Publication of IN2012DN00938A publication Critical patent/IN2012DN00938A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1  while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies  as well as the use of the antibodies in medicine  in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.
IN938DEN2012 2009-07-06 2010-07-06 IN2012DN00938A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27023909P 2009-07-06 2009-07-06
IE20090514A IE20090514A1 (en) 2009-07-06 2009-07-06 Humanised antibodies and uses therof
PCT/EP2010/059677 WO2011003925A1 (en) 2009-07-06 2010-07-06 Humanised antibodies to toll-like receptor 2 and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00938A true IN2012DN00938A (en) 2015-04-03

Family

ID=43428820

Family Applications (1)

Application Number Title Priority Date Filing Date
IN938DEN2012 IN2012DN00938A (en) 2009-07-06 2010-07-06

Country Status (16)

Country Link
US (1) US8734794B2 (en)
EP (2) EP2451842B1 (en)
JP (2) JP5847707B2 (en)
KR (1) KR101572171B1 (en)
CN (1) CN102482356B (en)
AU (1) AU2010270241B2 (en)
BR (1) BRPI1014016B8 (en)
CA (1) CA2766996C (en)
ES (2) ES2658224T3 (en)
IE (1) IE20090514A1 (en)
IL (1) IL217225A (en)
IN (1) IN2012DN00938A (en)
MX (1) MX2012000316A (en)
NZ (2) NZ615441A (en)
RU (1) RU2563344C2 (en)
WO (1) WO2011003925A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205633D0 (en) 2012-03-30 2012-05-16 Opsona Therapeutics Ltd Toll-like receptor 2 binding epitope and binding members thereto
EP2722342A1 (en) 2012-10-19 2014-04-23 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
KR101478426B1 (en) 2013-02-08 2014-12-31 아주대학교산학협력단 Biomarker for detecting white matter stroke comprising Toll-like receptor 2 and medical use thereof
US10370451B2 (en) * 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
CN103319600B (en) * 2013-06-19 2014-12-17 南京军区军事医学研究所 Humanized anti-TLR4 antibody Fab as well as preparation method and application thereof
MX2016011228A (en) 2014-02-28 2016-11-30 Astellas Pharma Inc Novel bispecific antibody binding to human tlr2 and human tlr4.
CN104403001B (en) * 2014-12-12 2018-01-16 中国人民解放军南京军区军事医学研究所 The monoclonal antibody of complete anti-TLR4 in people source a kind of and its whole immunoglobulin IgG and application
CN113980131A (en) 2015-01-30 2022-01-28 学校法人埼玉医科大学 anti-ALK 2 antibodies
FR3048971A1 (en) * 2016-03-15 2017-09-22 Univ Rabelais Francois BISPECIFIC PEPTIDE CONSTRUCTS AND THEIR USE IN THE TREATMENT OF DISEASES, IN PARTICULAR IMFLAMMATORY DISEASES
WO2018099614A1 (en) 2016-12-02 2018-06-07 Opsona Therapeutics Limited Methods and compositions for the treatment of myelodysplastic syndrome
EP3559204B1 (en) * 2016-12-22 2022-05-04 Avectas Limited Vector-free intracellular delivery by reversible permeabilisation
WO2018185284A1 (en) * 2017-04-07 2018-10-11 Miltenyi Biotec Gmbh POLYPEPTIDES WITH MUTANT HUMAN IgG4
JP7445977B2 (en) * 2018-01-29 2024-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Treatments for TLR2-mediated diseases and disorders
EP3583949A1 (en) 2018-06-19 2019-12-25 Opsona Therapeutics Limited Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer
KR20200050715A (en) * 2018-11-02 2020-05-12 주식회사 젠센 Composition for preventing or treating lupus comprising tlr-inhibiting peptides
CN111109198B (en) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 Method for constructing uveitis animal model
CN111393530A (en) * 2020-03-30 2020-07-10 中国人民解放军南部战区总医院 New humanized T L R2 extracellular segment monoclonal antibody and preparation method and application thereof
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
ATE448301T1 (en) 2000-09-08 2009-11-15 Univ Zuerich COLLECTION OF PROTEINS WITH REPEATING SEQUENCES (REPEAT PROTEINS) THAT CONTAIN REPETITIVE SEQUENCE MODULES
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
CN1809357B (en) * 2003-06-20 2010-12-22 科勒制药有限公司 Small molecule Toll-like receptor (TLR) antagonists
WO2005019431A2 (en) 2003-08-20 2005-03-03 University Of Massachusetts Selective inhibition of toll-like receptor-2
WO2005028509A1 (en) 2003-09-23 2005-03-31 Technische Universitaet Muenchen Tlr2 antagonistic antibody and use thereof
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CN101415438B (en) * 2004-11-30 2013-03-27 森托科尔公司 TOLL like receptor 3 antagonists, methods and uses
CN101115771B (en) 2005-02-03 2013-06-05 安迪拓普有限公司 Human antibodies and proteins
JP2009509535A (en) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド Proteinaceous drugs and their use
KR101361887B1 (en) 2006-03-02 2014-02-21 안티토페 리미티드 T cell assays
AU2008350535B2 (en) * 2007-05-14 2013-08-22 Novimmune S.A. Fc receptor-binding polypeptides with modified effector functions
EP2170366B1 (en) * 2007-08-03 2013-11-06 Opsona Therapeutics Limited Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage

Also Published As

Publication number Publication date
AU2010270241B2 (en) 2015-02-19
NZ615441A (en) 2014-10-31
WO2011003925A1 (en) 2011-01-13
EP2451842A1 (en) 2012-05-16
CN102482356A (en) 2012-05-30
ES2488615T3 (en) 2014-08-28
KR101572171B1 (en) 2015-11-26
BRPI1014016A2 (en) 2016-09-13
IL217225A (en) 2017-08-31
MX2012000316A (en) 2012-04-20
JP5847707B2 (en) 2016-01-27
IE20090514A1 (en) 2011-02-16
RU2563344C2 (en) 2015-09-20
ES2658224T3 (en) 2018-03-08
JP2016025863A (en) 2016-02-12
RU2011153932A (en) 2013-08-20
NZ597447A (en) 2013-12-20
EP2805973A3 (en) 2015-03-04
CN102482356B (en) 2016-05-25
JP2012531922A (en) 2012-12-13
CA2766996C (en) 2017-08-01
EP2805973B1 (en) 2017-11-08
US20120164159A1 (en) 2012-06-28
EP2451842B1 (en) 2014-05-14
CA2766996A1 (en) 2011-01-13
JP6677466B2 (en) 2020-04-08
IL217225A0 (en) 2012-02-29
BRPI1014016B1 (en) 2020-04-07
AU2010270241A1 (en) 2012-02-02
EP2805973A2 (en) 2014-11-26
BRPI1014016B8 (en) 2020-05-19
KR20120075457A (en) 2012-07-06
US8734794B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
IN2012DN00938A (en)
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ601271A (en) Cd127 binding proteins
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
EA201400568A1 (en) ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS
NZ607969A (en) Cd33 binding agents
MX2010009190A (en) HUMANIZED ANTI-C5aR ANTIBODIES.
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
EA201492149A1 (en) ST2 Antigen Binding Proteins
NZ703653A (en) Anti-fap antibodies and methods of use
NZ589436A (en) Dual variable domain immunoglobulins and uses thereof
PE20121361A1 (en) PCSK9 ANTAGONISTS
NZ597692A (en) Anti-IGF antibodies
EA201790757A1 (en) BONDING ANTIGEN CD27L PROTEINS
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX361929B (en) Neutralizing anti-ccl20 antibodies.
NZ595792A (en) Antibodies specific to cadherin-17
EA201390669A1 (en) METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY DISEASES OF THE NERVOUS SYSTEM
NZ594682A (en) Fully human antibodies specific to cadm1
NZ610091A (en) Antibodies
MX2016008520A (en) Novel anti-human bdca-2 antibody.
NZ624534A (en) Anti-fgfr2 antibodies and uses thereof
NZ623656A (en) Anti-αβtcr antibody
NZ603751A (en) Composition for treating disease